GlassScriptPhysician profile
Arthur Eugene Wood
NPI 1699718981
$1,260.48
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $154 · 2020: $213 · 2021: $408 · 2022: $125 · 2023: $160 · 2024: $200.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $360.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $359.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $232.43 | 2021-2024 | Vraylar |
| Astrazeneca Pharmaceuticals LP | $136.47 | 2019-2023 | Farxiga |
| Pfizer INC. | $129.30 | 2020-2021 | |
| Lilly USA, LLC | $93.94 | 2021-2024 | Mounjaro, Zepbound |
| Novartis Pharmaceuticals Corporation | $76.29 | 2022-2023 | |
| Hikma Pharmaceuticals USA | $70.04 | 2020-2021 | |
| Allergan, INC. | $61.02 | 2020 | |
| Janssen Pharmaceuticals, INC | $60.45 | 2020-2021 | |
| Sunovion Pharmaceuticals INC. | $55.19 | 2019 | |
| Merck Sharp & Dohme LLC | $48.53 | 2024 | Dificid |
| Novo Nordisk INC | $46.88 | 2019-2024 | Ozempic |
| Mylan Specialty L.P. | $45.82 | 2023-2024 | Yupelri |
| Glaxosmithkline, LLC. | $41.60 | 2020-2021 | |
| Amgen INC. | $40.48 | 2022-2024 | Repatha, Prolia, Evenity |
| Eyevance Pharmaceuticals LLC | $32.04 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $26.69 | 2019-2022 | |
| Xeris Pharmaceuticals, INC. | $18.69 | 2023 | Gvoke Hypopen |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.55 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $13.56 | 2019 | |
| Dexcom, INC. | $12.51 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arthur Wood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.